UK medicines regulator specs out independent future

26 June 2022

Breakups can be messy, but 18 months after the UK formally left the European Union, the newly-empowered Medicines and Healthcare products Regulatory Agency (MHRA) is determined to stay strong.

Transitioning from the old system to the new, the British medicines regulator has a lot of work to do, as well as significant opportunities to improve access to medicines.

Speaking at the Westminster Health Forum in London, chief partnerships officer Glenn Wells said the MHRA has an ambition to be a “World leading regulator,” focused on patient safety, adding the agency “now has strategies in place” to make that a reality.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber



Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Today's issue

Company Spotlight

More Features in Pharmaceutical